First siRNA Therapy Approved for Myasthenia Gravis
(MedPage Today) -- The FDA approved subcutaneous cemdisiran (Livsayis), a small interfering RNA (siRNA) therapy, to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive, Regeneron announced...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
